Search

Your search keyword '"Heyvaert, Frank"' showing total 6 results
Start Over Author "Heyvaert, Frank"
6 results on '"Heyvaert, Frank"'

1. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study

Author

Vervoort, Jascha, Lammens, Christine, Malhotra-Kumar, Surbhi, Goossens, Herman, Adriaenssens, Niels, Coenen, Samuel, Kowalczyk, Anna, Godycki-Cwirko, Maciek, Stewardson, Andrew J., Huttner, Benedikt, Harbarth, Stephan, Brossier, Caroline, Delémont, Cécile, de Tejada, Begoña Martinez, Renzi, Gesuele, Schrenzel, Jacques, Van Bylen, Sylvie, Vanbergen, Jonathan, Koeck, Philip, Leysen, Peter, Vandercam, Kim, Kluijtmans, Jacques, Borkiewicz, Agnieszka, Heyvaert, Frank, Michels, Nele, Deswaef, Gerd, Beckx, Tine, Declerck, Hadewijch, Embrechts, Katy, Verheyen, Nina, Bauwens, Tine, Béghin, Josefien, Verpooten, Liesbeth, Bombeke, Katrien, Vandenabeele, Tine, Muras, Magdalena, Świstak, Joanna, Wesołowska, Anna, Sterniczuk, Ewa, Brzozowska, Lidia, Cichowska, Krystyna, Szewczyk, Jolanta, Krupińska, Grażyna, Błaszczyk, Honorata, Stawińska, Urszula, Szyler, Maria, Kasielski, Marek, Rydz, Rafał, Myszkowska, Agata, Żebrowska, Lilianna, Stewardson, A.J., Vervoort, J., Adriaenssens, N., Coenen, S., Godycki-Cwirko, M., Kowalczyk, A., Huttner, B.D., Lammens, C., Malhotra-Kumar, S., Goossens, H., and Harbarth, S.

Published
2018
Full Text
View/download PDF

3. Effect of outpatient antibiotics for urinary tract infections on antimicrobial resistance among commensal Enterobacteriaceae: a multinational prospective cohort study

Author

Stewardson, A.J., primary, Vervoort, J., additional, Adriaenssens, N., additional, Coenen, S., additional, Godycki-Cwirko, M., additional, Kowalczyk, A., additional, Huttner, B.D., additional, Lammens, C., additional, Malhotra-Kumar, S., additional, Goossens, H., additional, Harbarth, S., additional, Vervoort, Jascha, additional, Lammens, Christine, additional, Malhotra-Kumar, Surbhi, additional, Goossens, Herman, additional, Adriaenssens, Niels, additional, Coenen, Samuel, additional, Kowalczyk, Anna, additional, Godycki-Cwirko, Maciek, additional, Stewardson, Andrew J., additional, Huttner, Benedikt, additional, Harbarth, Stephan, additional, Brossier, Caroline, additional, Delémont, Cécile, additional, de Tejada, Begoña Martinez, additional, Renzi, Gesuele, additional, Schrenzel, Jacques, additional, Van Bylen, Sylvie, additional, Vanbergen, Jonathan, additional, Koeck, Philip, additional, Leysen, Peter, additional, Vandercam, Kim, additional, Kluijtmans, Jacques, additional, Borkiewicz, Agnieszka, additional, Heyvaert, Frank, additional, Michels, Nele, additional, Deswaef, Gerd, additional, Beckx, Tine, additional, Declerck, Hadewijch, additional, Embrechts, Katy, additional, Verheyen, Nina, additional, Bauwens, Tine, additional, Béghin, Josefien, additional, Verpooten, Liesbeth, additional, Bombeke, Katrien, additional, Vandenabeele, Tine, additional, Muras, Magdalena, additional, Świstak, Joanna, additional, Wesołowska, Anna, additional, Sterniczuk, Ewa, additional, Brzozowska, Lidia, additional, Cichowska, Krystyna, additional, Szewczyk, Jolanta, additional, Krupińska, Grażyna, additional, Błaszczyk, Honorata, additional, Stawińska, Urszula, additional, Szyler, Maria, additional, Kasielski, Marek, additional, Rydz, Rafał, additional, Myszkowska, Agata, additional, and Żebrowska, Lilianna, additional

Published
2018
Full Text
View/download PDF

4. Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCT randomized trial results

Author

Kjeldsen, Sverre E, Sica, Domenic, Haller, Hermann, Cha, Gloria, Gil Extremera, Blas, Harvey, Peter, Heyvaert, Frank, Lewin, Andrew J., Villa, Giuseppe, Mancia, Giuseppe, the DISTINCT investigators: Agaiby, J, Aggarwal, N, Ainsworth, P, Akhras, R, Amaluan, V, Ballarin, A, Bardauskiene, L, Berra, Fc, Blagden, M, Bodalia, B, Borghi, C, Bundy, C, Burgess, L, Buynak, R, Cafferata, A, Cahill, T, Capiau, L, Capuano, V, Casanova, R, Cecil, J, Cha, G, Chapman, J, Chilvers, M, Christensen, S, Cho, Yh, Chung, Wb, Cipollone, F, Coca, A, Colombo, H, Contreras, Em, Crowley, D, Cusco Prieto, B, Decarlini, F, Doh, Jh, Dzongowski, P, Dzyak, G, Ellery, A, Extremera, Bg, Farias, E, Farrington, C, Fidelholtz, J, Fouche, L, Gabito, A, Gainza, M, Gani, M, Gaunt, R, Gelersztein, E, Giuliano, M, Glazunov, A, Glorioso, N, Goloschekin, B, Gumbley, M, Gupta, A, Guzman, L, Ha, Jw, Hart, R, Harvey, P, Haworth, D, Henein, S, Henry, D, Her, Sh, Heyvaert, F, Hollanders, G, Hominal, M, Hong, Bk, Hong, Tj, Hwang, Kk, Jacovides, A, Jacqmein, J, Jeon, Hk, Jones, N, Kanani, S, Kang, H, Karpenko, O, Kenton, D, Kimzey, N, Kjeldsen, Se, Kovalenko, V, Kushnir, M, Lasko, B, Lee, Kj, Lee, N, Lewin, A, Litvak, M, Luksiene, D, Majul, C, Mannarino, E, Manuale, O, Marcadis, A, Miller, D, Mills, R, Misik, K, Mortelmans, J, O'Mahony, M, O'Mahony, W, Park, C, Pedrinelli, Roberto, Petrulioniene, Z, Pettyjohn, F, Piskorz, D, Poss, G, Pudi, K, Pyun, Wb, Raad, G, Raila, G, Ramirez Espinosa MF, Ramlachan, P, Rhee, M, Rudenko, L, Ruiz, Ts, Ryan, J, Schacter, G, Shin, Jh, Short, D, Sica, D, Sirenko, Y, Slapikas, R, Somani, R, Stanislavchuk, M, Stewart, R, Svishchenko, Y, Sychov, O, Teitelbaum, I, Tseluyko, V, Van Rensburg DJ, Vaquer Perez JV, Via, Lm, Vico, M, Villa, G, Vizir, V, Vogel, D, Wellmann, H, Yoo, B. S., Kjeldsen, Sverre E, Sica, Domenic, Haller, Hermann, Cha, Gloria, Gil-Extremera, Bla, Harvey, Peter, Heyvaert, Frank, Lewin, Andrew J, Villa, Giuseppe, Mancia, Giuseppe, Borghi, Claudio, Kjeldsen, S, Sica, D, Haller, H, Cha, G, Gil-Extremera, B, Harvey, P, Heyvaert, F, Lewin, A, Villa, G, and Mancia, G

Subjects
Male, Physiology, Ethnic Group, Administration, Oral, Tetrazoles, Blood Pressure, DISTINCT study, Pharmacology, Benzimidazole, law.invention, combination therapy, Randomized controlled trial, candesartan cilexetil, combination therapy, DISTINCT study, essential hypertension, nifedipine GITS, vasodilatory side effects, law, Ethnicity, Tetrazole, Middle Aged, candesartan cilexetil, Biphenyl compound, Antihypertensive Agent, Treatment Outcome, Tolerability, Aged, Antihypertensive Agents, Benzimidazoles, Biphenyl Compounds, Double-Blind Method, Drug Therapy, Combination, Drug-Related Side Effects and Adverse Reactions, Ethnic Groups, Female, Humans, Hypertension, Nifedipine, Cardiology and Cardiovascular Medicine, Internal Medicine, Administration, Combination, Cardiology, Vasodilatory side effect, ORIGINAL PAPERS: Therapeutic aspects, medicine.drug, Human, Oral, medicine.medical_specialty, Side effect, Combination therapy, Drug Therapy, Internal medicine, medicine, vasodilatory side effects, business.industry, essential hypertension, nifedipine GITS, Candesartan, Blood pressure, Biphenyl Compound, business, Drug-Related Side Effects and Adverse Reaction
Abstract

Objectives: DISTINCT (reDefining Intervention with Studies Testing Innovative Nifedipine GITS – Candesartan Therapy) aimed to determine the dose–response and tolerability of nifedipine GITS and/or candesartan cilexetil therapy in participants with hypertension. Methods: In this 8-week, multinational, multicentre, randomized, double-blind, placebo-controlled study, adults with mean seated DBP of at least 95 to less than 110 mmHg received combination or monotherapy with nifedipine GITS (N) 20, 30 or 60 mg and candesartan cilexetil (C) 4, 8, 16 or 32 mg, or placebo. The primary endpoint, change in DBP from baseline to Week 8, was analysed using the response surface model (RSM); this analysis was repeated for mean seated SBP. Results: Overall, 1381 participants (mean baseline SBP/DBP: 156.5/99.6 mmHg) were randomized. Both N and C contributed independently to SBP/DBP reductions [P

Published
2014

5. Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCTrandomized trial results

Author

Kjeldsen, S, Sica, D, Haller, H, Cha, G, Gil-Extremera, B, Harvey, P, Heyvaert, F, Lewin, A, Villa, G, Mancia, G, Kjeldsen, Sverre E., Sica, Domenic, Haller, Hermann, Cha, Gloria, Gil-Extremera, Blas, Harvey, Peter, Heyvaert, Frank, Lewin, Andrew J., Villa, Giuseppe, Mancia, Giuseppe, Kjeldsen, S, Sica, D, Haller, H, Cha, G, Gil-Extremera, B, Harvey, P, Heyvaert, F, Lewin, A, Villa, G, Mancia, G, Kjeldsen, Sverre E., Sica, Domenic, Haller, Hermann, Cha, Gloria, Gil-Extremera, Blas, Harvey, Peter, Heyvaert, Frank, Lewin, Andrew J., Villa, Giuseppe, and Mancia, Giuseppe

Abstract

Objectives: DISTINCT (reDefining Intervention with Studies Testing Innovative Nifedipine GITS - Candesartan Therapy) aimed to determine the dose-response and tolerability of nifedipine GITS and/or candesartan cilexetil therapy in participants with hypertension. Methods: In this 8-week, multinational, multicentre, randomized, double-blind, placebo-controlled study, adults with mean seated DBP of at least 95 to less than 110mmHg received combination or monotherapy with nifedipine GITS (N) 20, 30 or 60mg and candesartan cilexetil (C) 4, 8, 16 or 32 mg, or placebo. The primary endpoint, change in DBP from baseline to Week 8, was analysed using the response surface model (RSM); this analysis was repeated for mean seated SBP. Results: Overall, 1381 participants (mean baseline SBP/ DBP: 156.5/99.6mmHg) were randomized. Both N and C contributed independently to SBP/DBP reductions [P < 0.0001 (RSM)]. A positive dose-response was observed, with all combinations providing statistically better blood pressure (BP) reductions from baseline versus respective monotherapies (P < 0.05) and N60C32 achieving the greatest reduction [-23.8/-16.5mmHg; P < 0.01 versus placebo (-5.3/-6.7 mmHg) and component monotherapies]. Even very low-dose (N20 and C4) therapy provided significant BP-lowering, and combination therapy was similarly effective in different racial groups. N/C combination demonstrated a lower incidence of vasodilatory adverse events than N monotherapy (18.3 versus 23.6%), including headache (5.5 versus 11.0%; P = 0.003, chi-square test) and peripheral oedema over time (3.6 versus 5.8%; n.s.). Conclusion: N/C combination was effective in participants with hypertension and showed an improved side effect profile compared with N monotherapy.

Published
2014

Catalog

Books, media, physical & digital resources
See catalog results